Incretin Atlas › Trials › REDEFINE 3
REDEFINE 3
CagriSema · Obesity + established CVD
Design
- Molecule(s)
- CagriSema
- Population
- Obesity + established CVD
- Official title
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- active not recruiting · 2023-03 → 2027-09
- Participants
- 7101
- Registry
- NCT05669755
Ongoing outcome trial
| Trial | Molecule | Population | Primary endpoint | n | Registry status | Primary completion | Registry |
|---|---|---|---|---|---|---|---|
| REDEFINE 3 | CagriSema | Obesity + established CVD Obesity + established CVD, with or without T2D | 3-point MACE | 7101 | active not recruiting | 2027-09-01 | NCT05669755 |
No results yet; the primary completion date comes from the registry.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: REDEFINE 3. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-3/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.